Antiphospholipid Syndrome Diagnosis and Management

Definition and Pathophysiology

Antiphospholipid syndrome (APS) is an autoimmune disorder driven by antiphospholipid antibodies that recognize phospholipid surfaces and phospholipid-binding proteins, inducing thrombosis, pregnancy morbidity, and other inflammatory manifestations 1
The pathophysiological mechanisms of APS include inhibition of prostacyclin formation, protein C activation, effects on platelets, limiting endothelium-derived relaxing factor production, and inhibition of fibrinolysis 2

Clinical Manifestations

Obstetric manifestations of APS include recurrent pregnancy loss, preeclampsia, and other pregnancy complications 3
Other clinical features of APS include thrombocytopenia, livedo reticularis, cardiac valve abnormalities, and neurological manifestations 2

Diagnostic Criteria

Diagnosis of APS requires both clinical criteria (thrombotic events or pregnancy morbidity) and laboratory criteria (persistent presence of antiphospholipid antibodies) 1
Laboratory testing for APS should include lupus anticoagulant (LAC), anticardiolipin antibodies (aCL), and anti-β2 glycoprotein-I antibodies (aβ2GPI) 1
Antibodies must be detected on two or more occasions at least 12 weeks apart 4
The 2023 ACR/EULAR classification criteria define moderate and high titer antiphospholipid antibody thresholds at 40 Units and 80 Units respectively 1
Triple positivity (positive for all three antibodies) indicates the highest risk for thrombotic events 4

Management of Thrombotic APS

For asymptomatic antiphospholipid antibody-positive patients, low-dose aspirin (75-100 mg daily) is recommended for primary prevention, especially in those with high-risk antibody profiles 5
For pregnant women with positive antiphospholipid antibodies who don't meet criteria for obstetric or thrombotic APS, prophylactic aspirin (81-100 mg daily) is conditionally recommended, starting before 16 weeks and continuing through delivery 3
For venous thrombosis, long-term anticoagulation with vitamin K antagonists (warfarin) with a target INR of 2.0-3.0 is strongly recommended 5
For arterial thrombosis, higher intensity anticoagulation (INR 3.0-4.0) may be considered 5

Management of Obstetric APS

For patients meeting criteria for obstetric APS, combined therapy with low-dose aspirin and prophylactic-dose heparin (usually low molecular weight heparin) is strongly recommended 3
In pregnant women with thrombotic APS, low-dose aspirin and therapeutic-dose heparin (usually low molecular weight heparin) should be used throughout pregnancy and postpartum 3
The addition of hydroxychloroquine to standard therapy is conditionally recommended for patients with primary APS, as recent studies suggest it may decrease complications 3

Management of Catastrophic APS

Aggressive treatment with a combination of anticoagulation, glucocorticoids, and plasma exchange is recommended for catastrophic APS 5

Monitoring and Follow-up

Regular monitoring of anticoagulation therapy is essential, with anti-Xa monitoring for patients on heparin or low molecular weight heparin 5
Patients with high-risk profiles (triple-positive or double-positive with LAC) require more intensive anticoagulation and closer monitoring 5
Pregnancy in APS patients requires additional monitoring due to increased risk of complications 3

Special Considerations

Antiplatelet/anticoagulation therapy is recommended for neuropsychiatric systemic lupus erythematosus related to antiphospholipid antibodies, especially for thrombotic cerebrovascular disease 6
Anticoagulation may be superior to antiplatelet therapy for secondary prevention of arterial events in APS 6

Management of Antiphospholipid Antibody Syndrome (APS)

Introduction to APS Management

For patients with confirmed APS requiring anticoagulation, adjusted-dose vitamin K antagonists (target INR 2.5) are recommended over direct oral anticoagulants (DOACs) during the treatment phase, as per the American College of Chest Physicians 7

Management of Obstetric APS

For patients meeting criteria for obstetric APS, combined therapy with low-dose aspirin and prophylactic-dose heparin is strongly recommended by the American College of Rheumatology 8

Management of Assisted Reproductive Technology (ART) in APS

In subfertile patients with APS who desire pregnancy, ART should be deferred if disease is moderately or severely active, according to the American College of Rheumatology 8
For patients with obstetric APS undergoing ART, strong recommendation for prophylactic anticoagulation with heparin or LMWH, as suggested by the American College of Rheumatology 8
For patients with thrombotic APS undergoing ART, strong recommendation for therapeutic anticoagulation, as per the American College of Rheumatology 8
Prophylactic LMWH should be started at the beginning of ovarian stimulation, withheld 24-36 hours prior to oocyte retrieval, and resumed following retrieval, as recommended by the American College of Rheumatology 8

Management of Antiphospholipid Syndrome

Risk Stratification and Management

APS patients should be stratified based on their antibody profile and clinical manifestations to guide management decisions, with high-risk profiles including presence of lupus anticoagulant, double or triple antibody positivity, or persistently high antibody titers, and low-risk profiles including isolated anticardiolipin or anti-β2-glycoprotein 1 antibodies at low-medium titers 9
Direct oral anticoagulants (DOACs) should be avoided in patients with triple-positive APS due to increased risk of arterial thrombosis, especially stroke 9
Statins may have a role in APS management due to their anti-inflammatory and immunomodulatory properties 9

Antiphospholipid Syndrome Treatment Guidelines

Treatment Recommendations

The American College of Chest Physicians recommends long-term anticoagulation with vitamin K antagonists (warfarin) with target INR 2.0-3.0 for venous thrombosis in patients with thrombotic APS 10
The American College of Rheumatology strongly recommends combined therapy with low-dose aspirin (81-100 mg daily) and prophylactic-dose heparin (usually low molecular weight heparin) for obstetric APS 11
For pregnant women with thrombotic APS, the American College of Rheumatology recommends therapeutic-dose heparin plus low-dose aspirin throughout pregnancy and postpartum 11
The American College of Chest Physicians recommends avoiding direct oral anticoagulants (DOACs) in triple-positive APS patients due to increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy 10
If a triple-positive APS patient is already on a DOAC, the American College of Chest Physicians recommends transitioning to warfarin therapy 12
The American College of Rheumatology suggests that adding hydroxychloroquine may be beneficial for patients with primary APS, as recent studies suggest it may decrease complications 11
For patients who fail standard therapy, the American College of Chest Physicians recommends considering increasing the target INR range 12
The American College of Rheumatology recommends considering hydroxychloroquine as adjunctive therapy for refractory APS 11

Anticoagulation Management for APS Patients with Sepsis

Introduction to Anticoagulation in APS

The American College of Chest Physicians recommends continuing therapeutic anticoagulation with warfarin (target INR 2.0-3.0) in APS patients with sepsis, unless there is active bleeding or a specific contraindication to anticoagulation 13

Rationale for Anticoagulation

Sepsis itself is prothrombotic and may increase thrombotic risk in APS patients, making anticoagulation critical 14, 15
Warfarin remains the gold standard for thrombotic APS with a target INR of 2.5 (range 2.0-3.0) 13

Monitoring and Management

INR monitoring may be unreliable in sepsis due to hepatic dysfunction and consumptive coagulopathy 14
Monitor for sepsis-induced coagulopathy (SIC): platelet count, PT-INR, and SOFA score 14, 15
If SIC develops, it does not contraindicate anticoagulation in APS 14, 15
Prophylactic anticoagulation with UFH or LMWH has been shown to reduce mortality in sepsis with SIC without increasing bleeding risk 15

Critical Considerations

The prothrombotic state of sepsis may synergize with APS thrombotic risk, making anticoagulation even more critical 14, 15
Do not withhold anticoagulation based on thrombocytopenia alone unless platelet count is critically low or there is active bleeding 14

Management of Catastrophic Antiphospholipid Syndrome (CAPS)

Foundation Therapy

The American College of Rheumatology recommends adding intravenous cyclophosphamide if CAPS occurs in the setting of SLE flare, as this addresses the underlying autoimmune trigger, with typical dosing: 500-1000 mg/m² monthly, synchronized with plasma exchange when possible 16

Antiphospholipid Syndrome Treatment Guidelines

Introduction to Antiphospholipid Syndrome Management

The American College of Rheumatology recommends combined low-dose aspirin (81-100 mg daily) plus prophylactic-dose low molecular weight heparin (LMWH) throughout pregnancy for patients with obstetric APS, with treatment started early (before 16 weeks) 17
For pregnant women with prior thrombotic APS, the American College of Rheumatology suggests using therapeutic-dose LMWH plus low-dose aspirin throughout pregnancy and postpartum 17
The American College of Rheumatology recommends considering adding hydroxychloroquine to the standard regimen for primary APS, as it may further decrease pregnancy complications 17
For pregnant women with positive aPL who don't meet full APS criteria, the American College of Rheumatology recommends starting prophylactic aspirin before 16 weeks as preeclampsia prophylaxis 17
The American College of Rheumatology advises against routinely using prophylactic heparin in asymptomatic aPL-positive patients unless additional high-risk features are present (triple-positive, advanced maternal age, IVF pregnancy) 17

Evidence‑Based Recommendations for Obstetric Antiphospholipid Syndrome

Late Pregnancy Complications

High‑risk antiphospholipid antibody profiles increase the odds of fetal growth restriction (IUGR) by 4.7‑fold【18】.
High‑risk antiphospholipid antibody profiles increase the odds of preeclampsia by 2.3‑fold【18】.

Risk Stratification

Triple‑positive patients (positive for lupus anticoagulant, anticardiolipin, and anti‑β2‑glycoprotein I) have the greatest risk for both thrombotic events and adverse pregnancy outcomes【18】.
Moderate‑to‑high antibody titers (≥ 40 units or ≥ 99th percentile) for anticardiolipin or anti‑β2‑glycoprotein I identify a significant risk of obstetric complications【19】.

Management Recommendations

Combined low‑dose aspirin (81–100 mg daily) plus prophylactic‑dose low‑molecular‑weight heparin is strongly recommended for all women meeting obstetric APS criteria, targeting platelet activation and coagulation pathways【19】.
Persistent positivity of antiphospholipid antibodies at moderate‑to‑high titers (≥ 40 units or ≥ 99th percentile) on two occasions ≥ 12 weeks apart is required for diagnostic confirmation and informs treatment decisions【19】.

Antibody‑Mediated Suppression of Placental‑Endometrial Inflammatory Protein Production

Pathophysiological Impact

Antiphospholipid/anti‑β2‑glycoprotein I antibodies bind to decidual and endometrial cells, resulting in reduced synthesis of inflammatory proteins required for proper maternal‑placental blood flow, which contributes to defective placentation and a higher risk of pregnancy loss 20

Management of Non‑Criteria Obstetric Antiphospholipid Syndrome

Diagnostic Work‑Up

All three criteria antiphospholipid antibodies (lupus anticoagulant, anticardiolipin IgG/IgM, anti‑β2‑glycoprotein I IgG/IgM) should be tested to confirm the laboratory diagnosis of obstetric APS. 21
Lupus anticoagulant is the strongest predictor of adverse pregnancy outcomes, with a relative risk of ≈ 12 (95 % CI 2.9–50.5); therefore it must be specifically evaluated in every patient. 22, 21

Risk Stratification

High‑risk features that may justify adding prophylactic‑dose low‑molecular‑weight heparin (LMWH) to aspirin (after shared decision‑making) include:
(Each of these features is supported by the guideline evidence.) 22, 21
Standard‑risk patients (single antibody positivity without high‑risk clinical features) are appropriately managed with aspirin alone. 22, 21

Treatment Recommendations

Aspirin 81–100 mg daily should be started before 16 weeks gestation and continued through delivery for all women with non‑criteria obstetric APS; this regimen provides prophylaxis against pre‑eclampsia, which is increased by aPL positivity. Conditional recommendation. 22, 21, 23
Addition of prophylactic‑dose LMWH (e.g., enoxaparin 40 mg SC daily or dalteparin 5,000 U SC daily) is not routinely recommended for non‑criteria obstetric APS; it may be considered only in the presence of the high‑risk features listed above. Conditional recommendation against routine use. 22, 21
Hydroxychloroquine should not be added to aspirin monotherapy in non‑criteria obstetric APS unless the patient has another indication such as systemic lupus erythematosus. Conditional recommendation against routine use. 22
Hydroxychloroquine may be used as an adjunct (not monotherapy) in confirmed primary APS, but this is a conditional recommendation and not applicable to non‑criteria obstetric APS without other indications. 23

Contraindicated or Discouraged Therapies

Routine prophylactic LMWH for all non‑criteria obstetric APS patients is conditionally discouraged due to insufficient benefit and potential harms. 22, 21
Intravenous immunoglobulin (IVIG) and high‑dose LMWH have no demonstrated benefit in refractory cases and should be avoided. 22
Prednisone should not be added to standard therapy; controlled trials are lacking and the risk profile is unfavorable. 22
Withholding low‑dose aspirin solely because of anesthesia concerns is not recommended; aspirin does not typically complicate delivery. 23

Evidence Summary & Safety Considerations

The 2020 American College of Rheumatology (ACR) guidelines issue a conditional recommendation against routine LMWH in non‑criteria obstetric APS, reflecting the paucity of robust randomized controlled trial data in this population. 22, 21
Emerging cohort data suggest possible benefit of combined aspirin + LMWH in selected women, but these studies are retrospective/prospective cohorts, not RCTs; therefore the guideline stance remains cautious. 22, 21
Prophylactic LMWH carries known risks—including bleeding, heparin‑induced thrombocytopenia, and osteoporosis with prolonged use—supporting the recommendation to avoid routine use. 22

All statements are derived from cited guideline evidence and reflect conditional (weak) recommendations where indicated.

Monitoring Antiphospholipid Syndrome (APS) in Pregnancy – Evidence‑Based Guidelines

1. Structured Monitoring Protocol

Pregnant individuals with APS should undergo monthly clinical assessments, serial fetal ultrasounds with Doppler starting at 16–20 weeks, blood‑pressure checks at every visit, and laboratory monitoring of renal function and serological markers at least once per trimester. 24, 25, 26

2. Maternal Clinical Assessment

Rheumatology or high‑risk obstetric visits are recommended at least once per trimester, with more frequent visits (every 2–4 weeks) for patients who are triple‑positive, lupus‑anticoagulant‑positive, or have concurrent systemic lupus erythematosus (SLE). 24
Blood‑pressure measurement at every prenatal visit is essential; preeclampsia occurs ~2.3‑fold more often in APS. 26

3. Laboratory Monitoring

Perform a complete blood count, urinalysis with protein‑to‑creatinine ratio, serum creatinine, and complement C3/C4 levels at least once per trimester. 24
Anti‑dsDNA antibodies should be checked in patients with concurrent SLE to differentiate disease flare from preeclampsia. 27
Declining complement (C3/C4) or rising anti‑dsDNA titers signal an increased risk of pregnancy loss, intra‑uterine growth restriction (IUGR), and preterm birth. 27

4. Fetal Surveillance Protocol

4.1 Ultrasound Schedule

First‑trimester ultrasound (11–14 weeks) to confirm viability and dating. 27, 25
Detailed anatomic survey with Doppler (20–24 weeks) to establish baseline uterine and umbilical‑artery flow. 27, 25
Monthly third‑trimester Doppler assessments beginning at 28 weeks (umbilical artery, uterine arteries, ductus venosus, middle cerebral artery). 27, 25
Increase surveillance to every 1–2 weeks after 32 weeks or sooner if abnormalities are detected. 27, 26

4.2 Specific Doppler Parameters

Umbilical‑artery Doppler to detect placental insufficiency. 27
Uterine‑artery Doppler to assess abnormal placentation and predict preeclampsia risk. 27
Middle‑cerebral‑artery Doppler to identify fetal anemia or hypoxia in growth‑restricted fetuses. 27
Cerebro‑placental ratio should be evaluated in late‑onset IUGR (≥34 weeks) because umbilical‑artery Doppler alone is insufficient. 27

4.3 Growth Assessment

Monthly fetal biometry in the third trimester to detect IUGR, which occurs ~4.7‑fold more frequently in high‑risk APS. 27, 26
Abdominal‑circumference growth velocity: a reduced velocity indicates a higher risk of adverse perinatal outcome. 27

5. Anticoagulation Management

5.1 Low‑Dose Aspirin

Continue low‑dose aspirin (81–100 mg daily) throughout pregnancy; routine laboratory monitoring is unnecessary, and aspirin does not complicate anesthesia or delivery. 24

5.2 Low‑Molecular‑Weight Heparin (LMWH)

6. High‑Risk Indicators Requiring Intensified Monitoring

Reduced fetal growth velocity or estimated fetal weight <10th percentile. 27
New‑onset or worsening hypertension. 24
New proteinuria or rising protein‑to‑creatinine ratio. 24
Declining complement levels or rising anti‑dsDNA titers in SLE patients. 27
Maternal symptoms suggestive of thrombosis or preeclampsia. 24

7. Post‑partum Monitoring

Therapeutic anticoagulation should be continued for 6–12 weeks postpartum in patients with thrombotic APS. 24
Blood‑pressure monitoring and symptom surveillance are required to detect postpartum preeclampsia. 24

8. Common Pitfalls to Avoid

Do not rely solely on umbilical‑artery Doppler after 34 weeks; incorporate cerebro‑placental ratio and abdominal‑circumference growth velocity. 27
Do not assume normal complement levels exclude an SLE flare; look for declining trends even within the normal range. 27
Do not discontinue aspirin before delivery solely due to anesthesia concerns; aspirin generally does not interfere with delivery. 24
Do not mistake physiological pregnancy changes for SLE activity; use validated pregnancy‑specific SLE activity indices. 27

Evidence‑Based Treatment Recommendations for Antiphospholipid Syndrome

Thrombotic APS – Venous Events

Lifelong warfarin therapy targeting an INR of 2.0–3.0 is the standard of care for patients with documented venous thromboembolism (deep‑vein thrombosis or pulmonary embolism) and persistent antiphospholipid antibodies 28.

Thrombotic APS – Arterial Events

Arterial APS (e.g., stroke) carries a higher recurrence risk than venous APS 28.
Two evidence‑based regimens are recommended:

Anticoagulant Choice – Avoidance of DOACs

Direct oral anticoagulants should be avoided in all APS patients, and rivaroxaban specifically is associated with excess recurrent arterial thrombosis compared with warfarin 28.

Warfarin Monitoring

For venous APS, maintain INR 2.0–3.0; for arterial APS (high‑intensity strategy), maintain INR 3.0–4.0 28.
INR should be checked at least monthly, with more frequent testing if the result is unstable 28.

Hydroxychloroquine in APS with Systemic Lupus Erythematosus (SLE)

Hydroxychloroquine should be continued throughout pregnancy in patients who have both APS and SLE 29.
In primary APS with concurrent SLE, antiplatelet or anticoagulant therapy is advised together with immunosuppression when lupus nephritis is present 29.
Patients with definite APS and SLE require full anticoagulation irrespective of the current level of lupus activity 29.

Peri‑operative Anticoagulation for Renal Transplant Candidates with APS

Transplantation should be delayed until clinical and serological lupus activity is absent or low for at least 3–6 months 29.
Individuals with moderate‑to‑high antiphospholipid antibody titers should receive peri‑operative anticoagulation during the transplant procedure 29.

Evidence‑Based Recommendations for Antiphospholipid Syndrome Management

Pregnancy Management

Hydroxychloroquine should be continued throughout pregnancy in patients with antiphospholipid syndrome to reduce pregnancy complications. 30

Catastrophic Antiphospholipid Syndrome

Immediate therapeutic anticoagulation with unfractionated heparin or low‑molecular‑weight heparin is recommended as the first step in managing catastrophic APS. 30
High‑dose intravenous glucocorticoids (e.g., methylprednisolone 500–1000 mg daily for 3–5 days, followed by oral prednisone 1 mg/kg/day) are part of the standard initial regimen for catastrophic APS. 30
Plasma exchange is associated with improved patient survival in retrospective studies and should be initiated promptly in catastrophic APS. 30
Rituximab has shown potential efficacy in catastrophic APS based on anecdotal reports. 30
Eculizumab, a complement C5 inhibitor, has emerging evidence of benefit in catastrophic APS because complement activation contributes to antibody‑mediated tissue injury. 30

APS Nephropathy

Long‑term warfarin anticoagulation is reasonable for APS nephropathy, achieving higher complete‑response rates (≈ 60 % vs 31 % with immunosuppression alone). 30
Direct oral anticoagulants are not recommended for APS nephropathy, as they are inferior to warfarin in preventing thromboembolic events. 30

Refractory Antiphospholipid Syndrome

Rituximab may be considered for patients with recurrent thrombosis despite optimal anticoagulation, although supporting evidence is limited. 30

Asymptomatic Antiphospholipid Antibody Carriers

Aggressive cardiovascular‑risk‑factor modification—including smoking cessation, blood‑pressure control, and lipid management—is essential in asymptomatic carriers. 31

Antiphospholipid Syndrome: Evidence‑Based Prevention and Management Guidelines

Primary Prevention in Asymptomatic aPL‑Positive Individuals

Aspirin 75–100 mg daily is strongly recommended for patients with high‑risk antiphospholipid antibody (aPL) profiles (triple‑positive, double‑positive, isolated lupus anticoagulant, or persistently high‑titer anticardiolipin) who have no prior thrombosis. This recommendation is based on the 2024 Stroke Society guideline. Class I, strong recommendation. 32
The same aspirin regimen applies to systemic lupus erythematosus (SLE) patients with high‑risk aPL profiles to reduce the risk of stroke, even in the absence of previous thrombotic events. Class I, strong recommendation. 33
For low‑risk aPL profiles (isolated anticardiolipin or anti‑β2‑glycoprotein I antibodies at low‑to‑medium titers, especially if transient), aspirin 75–100 mg daily may be considered after clinician‑patient discussion. Class IIa, moderate recommendation. 32
All three aPL assays (lupus anticoagulant, anticardiolipin IgG/IgM, anti‑β2‑glycoprotein I IgG/IgM) must be performed on two separate occasions ≥12 weeks apart before initiating any preventive therapy. Class I, strong recommendation. 33

Secondary Prevention of Thrombotic APS

Venous Thrombosis

Lifelong warfarin targeting an INR of 2.0–3.0 is the standard of care for patients with documented venous thromboembolism (deep‑vein thrombosis or pulmonary embolism) and persistent aPL positivity. This is a Class I, Level B‑NR recommendation from the American Heart Association. 34

Arterial Thrombosis (including stroke/TIA)

Two evidence‑based regimens are endorsed:
For patients presenting with ischemic stroke or transient ischemic attack who meet APS criteria, warfarin therapy is reasonable to reduce recurrent cerebrovascular events. Class IIa, moderate recommendation. 34

Isolated aPL Without Full APS Criteria

In individuals with isolated aPL positivity who experience ischemic stroke/TIA but do not fulfill APS classification, antiplatelet therapy alone (aspirin) is recommended because it offers lower bleeding risk compared with warfarin. Class IIa, moderate recommendation. 34

Direct Oral Anticoagulants (DOACs)

Rivaroxaban is contraindicated (Class III: Harm) in APS patients with a history of thrombosis and triple‑positive aPL, due to a higher rate of recurrent thrombotic events versus warfarin. Class III, strong recommendation. 34
All DOACs should be avoided in APS, especially in arterial disease or triple‑positive profiles, as evidence shows excess thrombotic risk. Class III, strong recommendation. [32][33]
For patients with a prior unprovoked venous thrombosis, a vitamin K antagonist targeting INR 2.0–3.0 is reasonable instead of aspirin or a DOAC. Class IIa, moderate recommendation. 33

Management During Pregnancy

Obstetric APS (≥3 early losses or ≥1 late loss)

Combined low‑dose aspirin (81–100 mg daily) plus prophylactic‑dose low‑molecular‑weight heparin (LMWH) throughout pregnancy is strongly recommended, achieving approximately 70 % live‑birth rates. Class I, strong recommendation from the American College of Rheumatology (2020). 35
Aspirin should be initiated before 16 weeks gestation and continued through delivery. Class I, strong recommendation. 35
Prophylactic LMWH (e.g., enoxaparin 40 mg SC daily) should be continued for 6–12 weeks postpartum to cover the heightened post‑delivery thrombotic risk. Class I, strong recommendation. 35

Thrombotic APS in Pregnancy

Therapeutic‑dose LMWH (enoxaparin 1 mg/kg SC twice daily or equivalent) together with low‑dose aspirin throughout pregnancy and the postpartum period is strongly recommended to prevent recurrent thrombosis in women with prior APS‑related events. Class I, strong recommendation. 35
Anticoagulation must be maintained for at least 6–12 weeks after delivery. Class I, strong recommendation. 35

Asymptomatic aPL‑Positive Pregnant Women (No Clinical APS)

Low‑dose aspirin 81–100 mg daily alone is advised, started before 16 weeks and continued through delivery, to modestly reduce obstetric complications. Class IIa, conditional recommendation. 35
Routine prophylactic LMWH is conditionally recommended against unless the patient exhibits very high‑risk features (triple‑positive aPL, strongly positive lupus anticoagulant, advanced maternal age, or IVF conception). Class IIb, conditional recommendation. 35

Adjunctive Therapy in Pregnancy

Hydroxychloroquine 200–400 mg daily may be added to standard therapy for primary APS; this conditional recommendation is based on small studies suggesting fewer pregnancy complications. Class IIb, conditional recommendation. 35

Laboratory Testing Recommendations

Screening for aPL in older adults with conventional vascular risk factors is not recommended, as evidence does not support systematic testing in this population. Class III, Harm (American Heart Association). 34
Testing for aPL is reasonable in younger patients with cryptogenic stroke, especially when there is a history of thrombosis or an underlying rheumatologic disease. Class IIa, moderate recommendation. 34

Adjunctive and Emerging Therapies in Antiphospholipid Syndrome

Adjunctive Pharmacologic Therapies

Statins are recommended as adjunctive therapy for patients with antiphospholipid syndrome who have high thrombotic risk or refractory disease, owing to anti‑inflammatory and immunomodulatory effects that extend beyond lipid‑lowering. Evidence derives from a 2019 observational study. 36

Investigational Targets

Targeting the interferon signaling pathway is being explored as a potential therapy for antiphospholipid syndrome, although clinical validation is still pending. The suggestion is based on a 2019 review of emerging mechanisms. 36

Direct Oral Anticoagulants (DOACs) – Evidence from Randomized Trial

A randomized trial in triple‑positive antiphospholipid syndrome comparing rivaroxaban with warfarin was stopped early because the rivaroxaban arm experienced a markedly higher rate of recurrent thrombosis (approximately 7‑fold increase). This high‑quality trial provides strong (Level A) evidence that DOACs are contraindicated in this subgroup. [36][37]

Cardiovascular Risk‑Factor Management

Comprehensive cardiovascular risk‑factor modification—including smoking cessation, blood‑pressure control, and lipid management—is essential for all carriers of antiphospholipid antibodies, as APS independently elevates cardiovascular disease risk. Recommendation is supported by expert consensus and a 2019 position paper. 36

Pathogenic Role of Anti‑β2‑Glycoprotein I Antibodies and Isotype‑Specific Risk in Antiphospholipid Syndrome

Autoantibody Targets and Pathogenic Mechanisms

Anti‑β2‑glycoprotein I (β2GPI) antibodies are identified as the principal auto‑antibodies driving lupus anticoagulant activity and are the critical pathogenic mediators of antiphospholipid syndrome (APS) 38.

Isotype‑Related Clinical Risk

IgG‑class antiphospholipid antibodies are clinically more relevant than IgM‑class antibodies for thrombotic manifestations of APS 38.
Isolated IgM antiphospholipid antibodies are observed more frequently in obstetric APS than in thrombotic APS, suggesting a distinct pathogenic role in pregnancy‑related disease [38][39].